Schering and Novartis tweak respiratory drug collaboration

Share this article:
In a joint statement today, Schering-Plough and Novartis announced changes to the collaboration agreements regarding both companies' respiratory portfolios.

Schering Plough will assume exclusive worldwide rights to develop and commercialize a fixed-dose combination of its Asmanex, an inhaled corticosteroid, and Novartis's Foradil, a beta2-adrenergic receptor agonist. As a tradeoff, Novartis will assume exclusive worldwide rights to develop and commercialize a fixed-dose combination of its investigational beta2-agonist QAB149 (indacaterol), and Schering-Plough's Asmanex. Previously, both combination therapies were to be developed and marketed as joint ventures.

The Asmanex/Foradil combination is currently in phase III trials for a chronic obstructive pulmonary disease (COPD) indication, having already completed phase III for asthma. The QAB149/Asmanex combination is in phase II trials for asthma and COPD.

The Novartis combo will utilize Schering's Twisthaler, a multi-dose dry powder inhaler device, for which Schering will receive royalties based on sales, according to the statement.

“Schering-Plough has a long history in developing therapies for treating respiratory diseases,” said Thomas Koestler, EVP and president, Schering-Plough Research Institute, in the statement, adding that the company hopes to submit an NDA for the Asmanex/Foradil combo, for asthma, by the end of June.

Asmanex was FDA approved for the treatment of asthma in 2005. Foradil is indicated for asthma and COPD, and received FDA approval in 2001.

In 2002, Schering-Plough and Novartis agreed to give Schering exclusive US distribution and marketing rights to Foradil. In 2003, the companies announced an agreement for joint worldwide development and marketing for the Asmanex/Foradil combo. In 2006, the companies announced a similar joint agreement for QAB149/Asmanex.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...